Adjuvant systemic treatment of early breast cancer: The NORA study

Annals of Oncology

Volumn 17, Issue 9, 2006, Pages 1386-1392

  Cazzaniga, M E ^a   Mustacchi, G ^b   Pronzato, P ^c   De Matteis, A ^d   Di Costanzo, F ^e   Floriani, I ^f  

^a TREVIGLIO HOSPITAL   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c La Spezia Hospital   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Cohort study

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CHOICE; EARLY CANCER; FEMALE; HUMAN; INFORMATION PROCESSING; ITALY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MENOPAUSE; PARTIAL MASTECTOMY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SYSTEMIC THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHOICE BEHAVIOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING;

EID: 33748740822     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl132     Document Type: Article

References (26)

1. Rosso S, Spitale A, Balzi D et al. Estimate of cancer incidence in Italian regions, 2001. Epidemiol Prev 2004; 28: 247-257.
2. Thuerlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast Cancer 2001; 8: 294-297.
3. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: Update International Expert Consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
4. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 21: 28-34.
5. Roila F, Ballatori I, Patoia L et al. Adjuvant systemic therapies in women with breast cancer: An audit of clinical practice in Italy. Ann Oncol 2003; 14: 843-848.
6. Stopeck AT. Women's health: The struggle to restore hormonal balance. Am J Med 2005; 118: 1181-1182.
7. Kinney A, Kline J, Levin B. Alcohol, caffeine and smoking in relation to age at menopause. Maturitas 2005; Oct 28.
8. Cutuli B, Cottu PH, Guastalla JP et al. A French national survey on infiltrating breast cancer: Analysis of clinico-pathological features and treatment modalities in 1159 patients. Breast Cancer Res Treat 2005; 1-10.
9. Schwartz AF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma of the breast April 19-22, 2001, Philadelphia, PA, USA. Breast J 2002; 8: 124-138.
10. Viale G, Maiorano E, Mazzarol G et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92: 1378-1384.
11. Corte MD, Rodil JA, Vazquez J et al. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA). J Cancer Res Clin Oncol 2005; 131: 701-714.
12. Colleoni M, Li S, Gelber RD et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366: 1108-1110.
13. Regan MM, Gelber RD. Predicting response to systemic treatments: learning from the past to plan for the future. Breast 2005; 14: 582-593.
14. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
15. Mouridsen H, Gershanovic M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
16. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
17. Cazzaniga ME, Mustacchi G, Pronzato P et al. Switching from tamoxifen (TAM) to aromatase inhibitors (Als) in the adjuvant treatment of breast cancer (BC) patients (PTS). Results from the NORA study. EBCC 2005, submitted.
18. Mustacchi G, Cazzaniga ME, Pronzato P et al. Influence of St Gallen guidelines for early breast cancer in Italian clinical practice. Results from NORA study. Ann Oncol 2005; 16: Vii 274-275.
19. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
20. Hutchins L, Green S, Ravdin P et al. CMF versus CAF with and without Tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup Trial Int 0102. Proc Am Soc Clin Oncol 1998; 17: 1a (Abstr 2).
21. Fisher B, Anderson S, Tan-Chiu E et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19: 931-942.
22. O'Leary J, Volm M, Wasserheit C et al. Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology (Williston Park) 1998; 12 (1 Suppl 1): 23-27.
23. Piccart M. The role of taxanes in the adjuvant treatment of early stage breast cancer. Breast Cancer Res Treat 2003; 79 (Suppl 1): S25-34.
24. Goldhirsch A, Gelber RD, Yothers F et al. Adjuvant treatment of very young women with breast cancer: Need for tailored treatments. J Nat Cancer Inst Monogr 2001; 30: 44-51.
25. International Breast Cancer Study Group: Randomised controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 2001; 10: 130-138.
26. Goldhirsch A, Glick JH, Gelber RD et al. Meeting Highlights: International Expert Concensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.